PRESS RELEASE
30 December 2024 16:42:00 CET

Change in the number of shares and votes in Egetis Therapeutics

Stockholm, Sweden, December 30, 2024. The number of shares and votes in Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) increased during December as a result of new share issues and the repurchase of 29,000,000 Class C shares, as announced on December 16, 2024. The purpose of the issuances and the repurchase is to secure the future delivery of shares to participants in, and to cover any social costs related to, ESOP 2021, ESOP 2022, ESOP 2023, and ESOP 2024. The Class C shares will be converted into ordinary shares prior to delivery to the program participants.
As of today, the last trading day of the month, there are a total of 388,238,126 shares, of which 359,238,126 are ordinary shares and 29,000,000 are Class C shares. As of December 30, 2024, the Company holds 29,000,000 Class C shares in treasury. Ordinary shares represent one vote per share, while Class C shares each represents 1/10th of a vote. The total number of votes amounts to 362,138,126, of which the ordinary shares correspond to 359,238,126 votes and the class C shares correspond to 2,900,000 votes. The share capital has increased by approximately SEK 1,526,316.36, from approximately SEK 18,907,276.842889 to approximately SEK 20,433,593.201760.

For further information, please contact

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com
+46 (0) 733 542 062

Yilmaz Mahshid, CFO
yilmaz.mahshid@egetis.com
+46 (0) 722 316 800

Karl Hård, Head of Investor Relations & Business Development
karl.hard@egetis.com
+44 (0) 7500 525 084

This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 16:42 CET.

PRESS RELEASE
30 December 2024 16:42:00 CET

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company's lead drug candidate tiratricol (Emcitate®) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) tiratricol has shown highly significant and clinically relevant results on serum thyroid hormone T3 concentrations and secondary clinical endpoints. In June 2024, topline results were presented from the Phase 2 study, Triac Trial II, with tiratricol for the treatment of MCT8 deficiency. The study investigated a potential additional treatment effect on neurocognitive development in young children under 30 months with MCT8 deficiency. The study did not show a statistically significant improvement compared to historical controls.

On December 12, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency.

After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in at least 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. As previously communicated, the Company will update the market as soon as recruitment closes, and at that time, the Company will also provide information on when to expect topline results and when the Company plans to submit the NDA application.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate calmangafodipir (Aladote®) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb/III study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for calmangafodipir has been parked until tiratricol marketing authorization submissions for MCT8 deficiency have been completed in the EU and the USA. Calmangafodipir has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com

Attachments

Change in the number of shares and votes in Egetis Therapeutics